CING (Cingulate) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Graphic logo of Cingulate (CING)

Cingulate Inc. (CING) develops stimulants for ADHD therapy in children and adults, leveraging innovations in the gradual release of active substances. In partnership with medical centers, Cingulate Inc. (CING) creates formulas to maintain a stable therapeutic effect. This chart of EV/EBITDA price dynamics reflects 0.00. However, the biotech's fate depends on the outcomes of new drug trials and the strict management of critically low cash reserves.

CING (Cingulate) Company Value to EBITDA history from 11/23/2025 to 11/10/2026

Comprehensive metric breakdowns and analytics for cingulate.com (CING)

- market price and analyst price targets:
Price Chart Cingulate|CING - Forecast Levels Chart
- business market valuation indicators:
Market Value Cingulate Inc.|CING - Company Buyout Price
- book value of equity indicators:
Accounting Value per Share Cingulate|CING - Total Stockholders' Equity|Market Capitalization to Book Value Ratio cingulate.com|CING - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital Cingulate Inc.|CING - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Cingulate|CING - Company Cumulative Debt|Debts to Book Capitalization Cingulate Inc.|CING - Company Long-Term Liabilities|Company Short-Term Debts Cingulate|Quick Liquidity cingulate.com
- net income and valuation multiples indicators:
CING - Company Profit|Projected Future Earnings Cingulate Inc.|CING - Market Cap to Net Income Ratio|Projected Price to Earnings Cingulate|CING - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cingulate Inc.|CING - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Cingulate|CING - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months cingulate.com|CING - Net earnings per one share growth for the current year|Earnings growth forecast for next year Cingulate Inc.
Initial company analysis:Cingulate Corp CING
Product sample of Cingulate

For Cingulate Inc. (CING), business valuation through the lens of operating profit is critical due to intense competition in the ADHD medication sector and regulatory pricing risks. By analyzing the EV/EBITDA multiple trend, an investor compares the total enterprise value (market capitalization and debt) with its ability to generate cash flow before taxes and depreciation, thereby determining the extent of the asset's overvaluation.

Competitors of Cingulate Inc. (CING)

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alkermes Inc. ALKS|AVDL (Avadel Corp) - Company Value to Operating Income Before Depreciation Ratio|ATAI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio ghres.com GHRS|MNMD (MindMed) - Enterprise Value to EBITDA Ratio|Company Value to EBITDA COMPASS Pathways PLC (CMPS)|LBRX (LB Pharma) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Bright Minds Corp (DRUG)|EV/EBITDA Multiple VNDA|CYBN (cybin.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alto Neuroscience ANRO|NRx Pharmaceuticals Inc. (NRXP) - Company Value to EBITDA|Silo Pharma - EV/EBITDA Multiple|China Pharma Holdings (CPHI) - Enterprise Value to EBITDA Ratio|CMND: EV/EBITDA Multiple|PBM - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SciSparc|Enterprise Value to Operating Income Before Depreciation SEEL (Seelos Therapeutics Inc.)|EV/EBITDA Multiple VRPX|Karuna Pharma (KRTX) - Enterprise Value to EBITDA Multiple